Createrna Receives Capital Injection from Well-known Investment Institutions
In August 2023, Vivo Capital, as a co-lead investor, successfully completed the A-round financing settlement with Wuhan Createrna Science and Technology Co., Ltd. (hereinafter referred to as “Createrna”). After the settlement, the total amount raised in the A-round financing reached RMB 500 million. Funds raised will be used to support Createrna’s product pipeline research and development, as well as expedited optimization and enhancements of clinical studies and key technological platforms. Createrna remains committed to fast-tracking its innovation R&D initiatives, aiming to translate innovative breakthroughs into industrialized, internationalized, and capitalized ventures. The ultimate objective is to emerge as a globally competitive, top-tier innovative pharmaceutical company in the specialized field.
About Vivo Capital
Founded in 1996, Vivo Capital is a globally leading healthcare investment firm dedicated to strategic empowerment and resource integration through an ecological strategy. Vivo Capital, through its diverse investment platforms encompassing venture capital, growth-stage private equity, control acquisitions, and public markets, manages a combined portfolio of 14 USD and RMB funds. The total assets under management amount to USD 6.4 billion, with investments in over 370 companies globally. All of Vivo Capital’s fund strategies extensively focus on investments in the healthcare sector, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a particular emphasis on the world’s largest healthcare markets. With a team of over 50 professionals, Vivo Capital is headquartered in Palo Alto, California, and maintains offices in Beijing, Shanghai, Hong Kong, Taipei, and Singapore.
Founded in 2013, Createrna is a high-tech enterprise specializing in innovative drug R&D, production, and operation. The Company has established innovative R&D centers in Wuhan and Shanghai, with a current workforce of over 240 employees. It has attracted several oversea senior experts and former experts of the United States Food and Drug Administration to join or support its drug research and development as well as business development. Following a R&D strategy developing drugs with unique and more advanced/favorable characteristics to address the unmet medical needs, Createrna’s pipelines cover several treatment areas including cardiovascular system, respiratory system, autoimmune disorders, pain, and kidney diseases. Its commitment lies in providing improved treatment options for patients. Through independent innovation and international collaborations, Createrna has cultivated a robust portfolio of drug R&D projects, encompassing over 20 pipelines currently at different development stages. Notably, eight pipelines have progressed to clinical stages from Phase 1 to Phase 3. Another four are in preclinical stage of drug development. Additionally, several pipelines have gained attention and interest from several international pharmaceutical companies listed in the Fortune Global 500, indicating promising prospects for intellectual property licensing.
2023-09-28Createrna Receives Capital Injection from Well-known Investment Institutions
2023-06-25Createrna Announces Completion of Series A Financing at Its Strategic Investment Press Conference in Wuhan
2022-07-17MY004567 tablets was approved by the FDA US. for clinical trials implied
2022-04-29Dr. Jing Zhang, formerly Head of the Clinical Team at the FDA's Center for Drug Approval, serves as CMO of Createrna